No Data
No Data
Chardan Research Initiates Cognition Therapeutics With Buy Rating, $11 Price Target
Cognition Therapeutics (CGTX) has an average buy rating and a price target range of $5 to $11, according to analysts polled by Capital IQ. Price: 1.9200, Change: +0.09, Percent Change: +4.92
Cognition Therapeutics Price Target Announced at $11.00/Share by Chardan Capital
Cognition Therapeutics Price Target Announced at $11.00/Share by Chardan Capital
Chardan Capital Initiates Coverage On Cognition Therapeutics With Buy Rating, Announces Price Target of $11
Chardan Capital analyst Daniil Gataulin initiates coverage on Cognition Therapeutics with a Buy rating and announces Price Target of $11.
Cognition Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/29/2024 352.49% HC Wainwright & Co. → $10 Initiates Coverage On → Buy 03/28/2024 126.24% B. Riley Secur
Express News | Cognition Therapeutics Inc : H.c. Wainwright Initiates Coverage With Buy Rating; Target Price $10
Buy Rating Affirmed for Cognition Therapeutics on Promising Alzheimer's Drug Candidate CT1812
No Data